跳至主要内容
临床试验/jRCT2041250146
jRCT2041250146进行中(未招募)不适用

Post-Trial Access (PTA) Program for Patients in Japan with Metachromatic Leukodystrophy who Received SHP611 While Participating either in the SHP611-201 or the HGT-MLD-071 Study

未提供0 个研究点目标入组 4 人开始时间: 待定
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
4

研究概览

简要总结

暂无简介。

研究设计

研究类型
Other
分配方式
Single Arm Study

入排标准

年龄范围
No limit 至 No limit(—)
性别
All

入选标准

  • The patient must be a resident of Japan and must be receiving SHP611 through either the SHP611-201 or the HGT-MLD-071 study.
  • The patient must derive continued benefit from SHP611 treatment in the opinion of their parent(s) or legally authorized representative(s) in consultation with their treating physician.
  • The patient must have no safety or medical issues that, in the opinion of the treating physician, would contraindicate participation.
  • The patient's parent(s) or legally authorized representative(s) must provide consent through the Information Sheet for participation in the program.

排除标准

  • Any patients with metachromatic leukodystrophy (MLD) not enrolled in either parent studies (SHP611-201 or the HGT-MLD-071) will not be eligible for participation in this program.

研究者

发起方
未提供

相似试验

Post-Trial Access (PTA) Program of SHP611 | 临床试验